Do elevated serum neural autoantibodies prove central nervous system injury?

Serum neural autoantibody results are biologically meaningful only when integrated with the neurologic syndrome, assay validity, and objective evidence of CNS involvement. This is particularly important in an 83-year-old, in whom diagnostic specificity is essential before attributing symptoms to autoimmune CNS disease or considering immunotherapy.

Clinical evidence

• A confirmed antigen-specific serum IgG can indicate immune recognition of its neural target. For example, amphiphysin IgG has been shown to bind the SH3 domain of amphiphysin, an intracellular synaptic-vesicle protein.
• Recognition is not equivalent to pathogenicity. Autoimmune encephalitis and paraneoplastic neurologic-syndrome frameworks require a compatible subacute phenotype, exclusion of competing causes, and supportive evidence from CSF, MRI, and/or EEG when appropriate.
• In a clinical testing cohort, only 46/148 (31%) serum-only positive results were associated with probable or definite autoimmune encephalitis or paraneoplastic neurologic syndrome, versus 29/32 (91%) CSF-only positive results. These cohort findings illustrate that serum positivity alone cannot establish antibody-mediated CNS injury.

Mechanistic and testing considerations

• Weak, isolated, or single-assay serum reactivity may be nonspecific, assay-dependent, or clinically irrelevant. Confirmation with an independent assay and/or tissue-based testing increases confidence in true antigen recognition.
• Diagnostic value depends on antibody and compartment: CSF is particularly informative for NMDAR and GFAP antibodies, whereas serum may be more sensitive for LGI1 and CASPR2. Paired serum-CSF testing, when feasible, helps resolve discordant findings.
• MRI, CSF inflammatory indices, and EEG provide complementary evidence of CNS inflammation or dysfunction; normal results do not individually exclude disease.

Bottom line

• Elevated serum neural autoantibodies provide at most plausible evidence of immune recognition when target-specific and confirmed. Without a compatible clinical syndrome and appropriate corroborating CSF, imaging, or electrophysiologic findings, they do not prove that antibodies are causing CNS injury.